Form 4: Vaxcyte SVP Exercises Stock Options and Sells Shares
SEC Form 4 Filing
Elvia Cowan, SVP of Finance at Vaxcyte, Inc., exercised stock options and sold shares on December 16, 2024.
Summary
- On December 16, 2024, Elvia Cowan, the SVP of Finance at Vaxcyte, Inc. (PCVX), exercised stock options to acquire 7,716 shares of common stock at a price of $25.92 per share.
- Simultaneously, Cowan disposed of 7,716 shares at $25.92 per share.
- Following these transactions, Cowan directly owns 106,284 stock options and 19,294 shares of Vaxcyte common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it's a routine insider transaction.
- Shareholders may be interested in insider trading activity as an indicator of management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| July 1, 2023 | 1/4 of the shares subject to the option vested. |
| December 16, 2024 | Earliest transaction date: Stock options exercised and shares disposed of. |
| December 18, 2024 | Date of signature for the Form 4 filing. |
| August 08, 2032 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.